Perrigo Seals Sale of Dermacosmetics Business to Karo Healthcare

Perrigo Completes the Sale of Its Dermacosmetics Division

Perrigo Company plc, listed on the NYSE as PRGO, announced a significant milestone in its restructuring efforts with the completion of the sale of its Dermacosmetics business to Karo Healthcare. This strategic divestiture, finalized on April 30, 2026, brings in upfront net proceeds of approximately €306 million, which will be primarily allocated towards debt reduction to enhance the company's financial health.

Strategic Implications of the Sale

This transaction is not merely a financial maneuver; it’s a key component of Perrigo’s Three-S plan, which aims to stabilize, streamline, and strengthen the company's operations. According to Patrick Lockwood-Taylor, the company’s President and CEO, the divestiture allows Perrigo to sharpen its focus on core categories. By doing so, Perrigo is better positioned to tap into its competitive advantages and foster sustainable growth in shareholder value.

Perrigo’s Dermacosmetics division, which includes popular brands such as ACO, Biodermal, Emolium, and Iwostin, reported approximately €120 million in net sales in 2025. This accounted for about 5% of the company’s adjusted operating income. The decision to sell reflects a strategic pivot to prioritize more profitable segments of its portfolio.

Financial Breakdown of the Transaction

The transaction involved a total consideration of up to €332.6 million, comprising €305.6 million in immediate cash and additional contingent payments contingent upon achieving specified net sales milestones in the following three years. This structure not only provides Perrigo with immediate liquidity for debt reduction but also aligns incentives for Karo Healthcare to drive growth post-acquisition.

Perrigo’s advisory team for this sale included Greenhill & Co. as the financial advisor, while Latham & Watkins handled legal matters. Their expertise in navigating such complex transactions plays a crucial role in ensuring value is maximized for shareholders during this transition phase.

Perrigo’s Commitment to Growth

As a leading self-care company with over a century of experience, Perrigo has consistently focused on providing high-quality health products and wellness solutions mainly in North America and Europe. Their unique business model integrates cash-generative store brand offerings, which support investments in leading brands, positioning Perrigo as a trusted powerhouse in the consumer health market.

The divestiture of Dermacosmetics also illustrates the company’s methodical approach to focusing on key sectors that align with its vision for sustainable growth. The funds from this transaction will allow Perrigo to not only alleviate financial pressures but also better invest in other core categories that promise higher returns and consumer relevance.

Looking Ahead

Moving forward, Perrigo’s leadership is optimistic about utilizing the proceeds from the Dermacosmetics sale to enhance financial flexibility, strengthen the balance sheet, and invest in growth initiatives. The company is committed to refining its operational strategy to ensure long-term success and shareholder confidence.

In conclusion, Perrigo's sale of its Dermacosmetics business is more than a simple divestiture; it's part of a broader strategy to streamline operations and focus on segments that will yield the most sustainable growth. Investors and consumers alike can anticipate a strong future as Perrigo navigates these changes with careful planning and execution.

For more information about Perrigo and its latest updates, visit Perrigo’s official website.